Industries

Pharma and biotech

GMP requirements, temperature-sensitive shipments and serialisation create a chain where evidence matters at every hand-off, and dependence on imported active ingredients adds exposure. Decisions on shipments, stock and supply are taken by people, by your own ERP planning and replenishment rules, and by the agents of logistics providers and procurement vendors. Aidecis gives them one authority model and one decision record, while batch release stays with your Qualified Person and your quality system.

Current challenges

  • Cold-chain excursions or missing readings can put a batch on hold.
  • Ingredient shortages and supplier changes require quality review.
  • Teams must preserve reliable evidence across production, distribution and serialisation records.

How Aidecis helps

  • Register the software that already decides, such as MRP and replenishment rules, cold-chain monitoring alerts, and logistics-provider or procurement agents, with an owner, limits and a mode.
  • Enforced control: your own integration checks Aidecis's single-use grant before a proposed action runs, and is held when evidence is missing or conflicting, such as a gap in temperature readings.
  • Observed control: when a logistics provider's or supplier's agent changes a shipment or an order in its own system, Aidecis reads the change afterwards, checks it against that agent's role and limits, and flags it within minutes if it went outside them. It does not prevent the change.
  • Route deviations and source changes to the designated quality and authority owners, with the supporting evidence attached.
  • Automation stays low on the scale: agents and algorithms prepare evidence and propose (autonomy level 1 to 2), and a qualified person decides. Batch disposition, GMP deviations and release never move to bot mode.
  • How far a decision may climb also depends on your maturity in that decision family. For basic or digital organisations we propose reviewed assistance and bounded pilots, not bot mode. Agent-to-agent chains are opened one chain at a time, as a bounded pilot, never by default.

Benefits

  • Earlier visibility of avoidable holds and supply risks.
  • Less time assembling evidence for exception reviews.
  • Clearer accountability while authorised quality processes retain release responsibility.

We agree a baseline with your team, measure every benefit in the pilot and count each one once.

Operating context

GMP, distribution requirements and serialisation obligations where applicable.

Benefits

What could this mean for your network?

Explore potential benefits and your investment.

Calculate benefits and investment